Abstract
Hypertension is traditionally considered a disease in which elevated blood pressure contributes to inflammation and activation of the immune system, leading to cardiovascular injury and end-organ damage. Here, we discuss the effects of aldosterone on the immune system and aldosterone’s contribution to vascular pathogenesis. Studies in human have suggested a broader role for aldosterone, beyond elevating blood pressure. Recent clinical data support the notion that aldosterone can directly alter the function of the immune system and cause vascular-damaging inflammation. Clinical observations have been reproduced in experimental models of hypertension, further supporting the idea that an aberrant immune response contributes to the onset of hypertension. Such studies have shown that myeloid cells are required to induce the disease and IL-17-producing CD4+ T cells may contribute to maintaining aldosterone-mediated hypertension. In addition, regulatory T cells diminish the inflammatory damage caused by aldosterone during hypertension. This is a very active area of research that could lead to new therapeutic targets for treating hypertension.
Keywords: Aldosterone, GPR30, hypertension, inflammation, mineralocorticoid receptor.
Current Molecular Medicine
Title:Immune System Alterations by Aldosterone During Hypertension: From Clinical Observations to Genomic and Non-Genomic Mechanisms Leading to Vascular Damage
Volume: 13 Issue: 6
Author(s): N. Munoz-Durango, M.F. Barake, N.A. Letelier, C. Campino, C.E. Fardella and A.M. Kalergis
Affiliation:
Keywords: Aldosterone, GPR30, hypertension, inflammation, mineralocorticoid receptor.
Abstract: Hypertension is traditionally considered a disease in which elevated blood pressure contributes to inflammation and activation of the immune system, leading to cardiovascular injury and end-organ damage. Here, we discuss the effects of aldosterone on the immune system and aldosterone’s contribution to vascular pathogenesis. Studies in human have suggested a broader role for aldosterone, beyond elevating blood pressure. Recent clinical data support the notion that aldosterone can directly alter the function of the immune system and cause vascular-damaging inflammation. Clinical observations have been reproduced in experimental models of hypertension, further supporting the idea that an aberrant immune response contributes to the onset of hypertension. Such studies have shown that myeloid cells are required to induce the disease and IL-17-producing CD4+ T cells may contribute to maintaining aldosterone-mediated hypertension. In addition, regulatory T cells diminish the inflammatory damage caused by aldosterone during hypertension. This is a very active area of research that could lead to new therapeutic targets for treating hypertension.
Export Options
About this article
Cite this article as:
Munoz-Durango N., Barake M.F., Letelier N.A., Campino C., Fardella C.E. and Kalergis A.M., Immune System Alterations by Aldosterone During Hypertension: From Clinical Observations to Genomic and Non-Genomic Mechanisms Leading to Vascular Damage, Current Molecular Medicine 2013; 13 (6) . https://dx.doi.org/10.2174/1566524011313060015
DOI https://dx.doi.org/10.2174/1566524011313060015 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Traditional Cardiovascular Risk Factors in Adolescents with Type 1 Diabetes Mellitus
Current Diabetes Reviews Association of Lipoprotein-associated Phospholipase A2 Activity with Components of the Metabolic Syndrome in Apparently Healthy Boys
Cardiovascular & Hematological Agents in Medicinal Chemistry Treatment of Hypertensive Complications in Pregnancy
Current Pharmaceutical Design Hypertension and Atrial Fibrillation: Any Change with the New Anticoagulants
Current Pharmaceutical Design Troponin in Newborns and Pediatric Patients
Cardiovascular & Hematological Agents in Medicinal Chemistry Sympathetic Overactivity in Patients with Chronic Renal Failure - The Culprit of Increased Cardiovascular Mortality?
Current Hypertension Reviews Does Metabolic Syndrome or its Individual Components Affect Pain and Function in Knee Osteoarthritis Women?
Current Rheumatology Reviews Chemistry and Effects of Brainstem Acting Drugs
Central Nervous System Agents in Medicinal Chemistry Vascular Smooth Muscle Relaxation by a Lectin from Pisum arvense: Evidences of Endothelial NOS Pathway
Protein & Peptide Letters Atheromatosis Extent in Coronary Artery Disease is not Correlated with Apolipoprotein-E Polymorphism and its Plasma Levels, but Associated with Cognitive Decline
Current Alzheimer Research Subject Index to Volume 4
Current Drug Targets - Cardiovascular & Hematological Disorders Protein Kinase C Isoforms - Implications to Thrombosis
Current Signal Transduction Therapy Glaucoma Drug Therapy in Pregnancy: Literature Review and Teratology Information Service (TIS) Case Series
Current Drug Safety Inflammation-Mediating Proteases: Structure, Function in (Patho) Physiology and Inhibition
Protein & Peptide Letters Patent Selections
Recent Patents on Cardiovascular Drug Discovery Pathophysiological Implications of Dipeptidyl Peptidases
Current Protein & Peptide Science Current Perspectives on Anti-Aging Interventions
Letters in Drug Design & Discovery Managing Erectile Dysfunction in Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Glomerular Endothelium and its Impact on Glomerular Filtration Barrier in Diabetes: Are the Gaps Still Illusive?
Current Medicinal Chemistry Development of Inhibitors of the Aspartyl Protease Renin for the Treatment of Hypertension
Current Protein & Peptide Science